VF
IMNM icon

Virtu Financial’s Immunome IMNM Stock Holding History

Virtu Financial’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-45,743
Closed -$486K – 1668
2024
Q4 		$486K Buy
+45,743
New +$553K 0.03% 507
2021
Q4 		– Sell
-10,904
Closed -$266K – 1927
2021
Q3 		$266K Buy
+10,904
New +$190K 0.02% 778

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Virtu Financial's IMNM Position: Q1 2025 in Review

Virtu Financial sold out of Immunome (IMNM) in Q1 2025, closing a stake of 45,743 shares — an estimated $486K sold.

Virtu Financial first reported a position in IMNM in Q3 2021 and held it in 2 quarters. The position peaked at $486K in Q4 2024. 142 funds tracked by Wall St. Rank hold IMNM as of Q1 2025.

  • Virtu Financial reported no remaining Immunome position as of Q1 2025 after selling out during the quarter.
  • Virtu Financial sold 45,743 Immunome shares in Q1 2025, an estimated $486K.
  • Virtu Financial first reported a position in Immunome in Q3 2021 and held it in 2 quarters.
  • Virtu Financial's Immunome position peaked at $486K in Q4 2024.
  • 142 funds tracked by Wall St. Rank held Immunome as of Q1 2025.

Based on Virtu Financial's 13F filing for Q1 2025, filed 12 May 2025.